Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company focusing on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. In 2015, an estimated 231,840 women in the United States were diagnosed with invasive breast cancer, and an estimated 60,000 U.S. women were diagnosed with non-invasive in situ carcinoma. Of those, approximately 40,000 women died from breast cancer. The company’s leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts, which may provide a higher concentration of the therapeutic to the target tissue. In March 2016, a phase 2 clinical study was initiated using microcatheters to deliver FDA-approved fulvestrant as a potential treatment of ductal carcinoma in-situ (DCIS) and breast cancer. In addition to its intraductal microcatheters, Atossa also has several pending patent applications directed to the treatment of breast conditions and cancer by the intraductal administration of therapeutics, including fulvestrant.
To learn more, visit www.atossagenetics.com
About Atossa Genetics
Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
